Edition:
United Kingdom

Ionis Pharmaceuticals Inc (IONS.OQ)

IONS.OQ on NASDAQ Stock Exchange Global Select Market

44.07USD
23 May 2018
Change (% chg)

$0.27 (+0.62%)
Prev Close
$43.80
Open
$43.55
Day's High
$44.30
Day's Low
$43.55
Volume
67,694
Avg. Vol
386,298
52-wk High
$65.51
52-wk Low
$39.08

Latest Key Developments (Source: Significant Developments)

Ionis And AstraZeneca Advance New Drug For NASH
Monday, 9 Apr 2018 

April 9 (Reuters) - Ionis Pharmaceuticals Inc ::IONIS AND ASTRAZENECA ADVANCE NEW DRUG FOR NASH.IONIS PHARMACEUTICALS INC - EARNS $30 MLN LICENSE FEE FOR IONIS-AZ6-2.5-L RX.IONIS PHARMACEUTICALS INC - ASTRAZENECA WILL BE RESPONSIBLE FOR FURTHER DEVELOPMENT & COMMERCIALIZATION OF IONIS-AZ6-2.5-LRX.IONIS PHARMACEUTICALS INC - AS IONIS-AZ6-2.5-LRX ADVANCES, CO MAY RECEIVE UP TO $300 MLN IN ADDITIONAL DEVELOPMENT & REGULATORY MILESTONE PAYMENTS.  Full Article

Ionis Pharmaceuticals Announces Initiation Of Clinical Study Of First Orally Delivered Antisense Drug For Treatment Of Gastrointestinal Disorders
Thursday, 21 Dec 2017 

Dec 21 (Reuters) - Ionis Pharmaceuticals Inc ::IONIS PHARMACEUTICALS ANNOUNCES THE INITIATION OF A CLINICAL STUDY OF ITS FIRST ORALLY DELIVERED ANTISENSE DRUG FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS.IONIS PHARMACEUTICALS- UNDER AGREEMENT WITH JANSSEN, CO TO RECEIVE NEARLY $585 MILLION IN DEVELOPMENT, REGULATORY, SALES MILESTONE PAYMENTS & LICENSE FEES.IONIS PHARMACEUTICALS INC - EARNED $5 MILLION MILESTONE PAYMENT ASSOCIATED WITH INITIATION, ENROLLMENT IN PHASE 1 CLINICAL STUDY OF IONIS-JBI1-2.5(RX).IONIS PHARMACEUTICALS INC - JANSSEN BIOTECH IS CONDUCTING PHASE 1 STUDY.  Full Article

Biogen, Ionis Collaborate To Identify Novel Therapies To Treat Spinal Muscular Atrophy
Tuesday, 19 Dec 2017 

Dec 19 (Reuters) - Biogen Inc ::BIOGEN AND IONIS ENTER INTO NEW COLLABORATION TO IDENTIFY NOVEL THERAPIES FOR THE TREATMENT OF SPINAL MUSCULAR ATROPHY.BIOGEN WILL HAVE OPTION TO LICENSE THERAPIES ARISING OUT OF THE COLLABORATION.‍IONIS WILL RECEIVE A $25 MILLION UPFRONT PAYMENT AND WILL EARN DEVELOPMENT AND REGULATORY MILESTONE PAYMENTS FROM BIOGEN.BIOGEN WILL BE RESPONSIBLE FOR THE DEVELOPMENT AND COMMERCIALIZATION.ON COMMERCIALIZATION OF NOVEL THERAPIES TO TREAT SPINAL MUSCULAR ATROPHY​, BIOGEN TO PAY IONIS PERFORMANCE MILESTONES, ROYALTIES ON NET SALES.  Full Article

Ionis' License Agreement For Huntington's Disease Drug Receives Hart-Scott-Rodino Clearance
Monday, 18 Dec 2017 

Dec 18 (Reuters) - Ionis Pharmaceuticals Inc ::IONIS' LICENSE AGREEMENT FOR HUNTINGTON'S DISEASE DRUG, IONIS-HTT RX, RECEIVES HART-SCOTT-RODINO CLEARANCE.IONIS PHARMACEUTICALS INC - IONIS HAS EARNED A $45 MILLION LICENSE FEE FROM ROCHE.IONIS PHARMACEUTICALS INC - ROCHE IS NOW RESPONSIBLE FOR ALL IONIS-HTT(RX) DEVELOPMENT, REGULATORY AND COMMERCIALIZATION ACTIVITIES AND COSTS.  Full Article

Ionis Pharma Says Roche Has Exercised Option To License IONIS-HTT(Rx)
Monday, 11 Dec 2017 

Dec 11 (Reuters) - Ionis Pharmaceuticals Inc ::IONIS PHARMACEUTICALS LICENSES IONIS-HTT RX TO PARTNER FOLLOWING SUCCESSFUL PHASE 1/2A STUDY IN PATIENTS WITH HUNTINGTON'S DISEASE.IONIS PHARMA SAYS ROCHE HAS EXERCISED OPTION TO LICENSE IONIS-HTT(RX).IONIS PHARMACEUTICALS INC - ROCHE WILL NOW BE RESPONSIBLE FOR ALL DEVELOPMENT AND COMMERCIAL ACTIVITIES FOR IONIS-HTT(RX).IONIS PHARMACEUTICALS INC - IN CONJUNCTION WITH DECISION TO LICENSE IONIS-HTT(RX), IONIS EARNED A $45 MILLION LICENSE FEE FROM ROCHE..  Full Article

Ionis eligible to get nearly $800 mln in milestones from deal with Janssen
Thursday, 16 Nov 2017 

Nov 16 (Reuters) - Ionis Pharmaceuticals Inc -:Ionis Pharmaceuticals licenses second orally delivered antisense drug to Janssen.Ionis Pharmaceuticals - licensed second orally delivered generation 2.5 antisense drug to Janssen Biotech, Inc. for which Ionis earned $5 million​.Ionis Pharmaceuticals -Janssen to now assume all global development, regulatory, commercialization responsibilities for IONIS-JBI2-2.5(RX )for GI diseases​.Ionis Pharma- ‍under global collaboration deal with Janssen, co eligible to receive nearly $800 million in regulatory, sales milestone payments, others.Ionis Pharma- ‍in addition, will receive tiered royalties that on average are double-digits on sales from any product that is successfully commercialized​.Ionis Pharmaceuticals Inc - ‍IONIS-JBI1-2.5(RX), first collaboration target, was licensed to Janssen last year.  Full Article

Akcea and Ionis announce acceptance of marketing applications in U.S., EU and Canada for Volanesorsen
Wednesday, 15 Nov 2017 

Nov 15 (Reuters) - Akcea Therapeutics Inc :Akcea and Ionis announce acceptance of marketing applications in U.S., EU and Canada for Volanesorsen for the treatment of FCS.Akcea Therapeutics Inc - ‍in U.S., Food And Drug Administration assigned a prescription drug user fee act goal date of August 30, 2018​.Akcea Therapeutics Inc - marketing applications for Volanesorsen been accepted for review in U.S., EU & Canada for treatment of patients with FCS.  Full Article

Ionis Pharma, ‍Dynacure announces Dynacure has licensed IONIS-DNM2-2.5(Rx) (Dyn101)​
Thursday, 9 Nov 2017 

Nov 9 (Reuters) - Ionis Pharmaceuticals Inc :Ionis Pharmaceuticals Inc - co, ‍Dynacure announced that Dynacure has licensed IONIS-DNM2-2.5(Rx) (Dyn101)​.Ionis Pharmaceuticals Inc - ‍Dynacure will now assume all development and commercialization responsibilities for program​.Ionis Pharmaceuticals Inc - ‍Ionis is eligible to receive additional cash or equity of up to more than $205 million in milestone payments​.Ionis Pharmaceuticals Inc - ‍Ionis is eligible to receive royalties on future product sales of drug under this collaboration​.  Full Article

Ionis Pharmaceuticals reports Q3 earnings per share $0.00
Tuesday, 7 Nov 2017 

Nov 7 (Reuters) - Ionis Pharmaceuticals Inc :Ionis Pharmaceuticals reports financial results and highlights for third quarter 2017.Q3 earnings per share $0.00.Q3 earnings per share view $0.01 -- Thomson Reuters I/B/E/S.Ionis Pharmaceuticals Inc - ‍on track to meet its 2017 guidance​.Ionis Pharmaceuticals Inc - ‍qtrly revenue $120.9 million versus $110.9 million.Ionis Pharmaceuticals Inc - ‍projecting an increase in operating expenses for Q4 of 2017 compared to Q3 of 2017​.Q3 revenue view $117.0 million -- Thomson Reuters I/B/E/S.Fy2017 earnings per share view $-0.16, revenue view $438.8 million -- Thomson Reuters I/B/E/S.  Full Article

IONIS PHARMACEUTICALS TO COLLABORATE WITH SEVENTH SENSE BIOSYSTEMS
Wednesday, 18 Oct 2017 

Oct 18 (Reuters) - Ionis Pharmaceuticals Inc ::IONIS ENTERS INTO COLLABORATION WITH SEVENTH SENSE BIOSYSTEMS TO SUPPORT DEVELOPMENT OF IMPROVED BLOOD COLLECTION AND DIAGNOSTIC DEVICE.IONIS PHARMACEUTICALS INC - ‍AS PART OF ITS COMMITMENT TO COLLABORATION, CO MADE INVESTMENT OF $2 MILLION IN 7SBIO AS PART OF A SERIES C FINANCING​.  Full Article

BRIEF-Ionis Reports Q1 Total Revenue Of $144 Mln Vs $116 Mln

* FOR Q1 OF 2018, BASIC AND DILUTED NET LOSS PER SHARE WERE $0.01 Source text for Eikon: Further company coverage: